消化系统神经内分泌癌免疫治疗研究现状

陆明; 张盼盼; 沈琳

doi:10.12376/j.issn.2097-0501.2022.01.006

消化系统神经内分泌癌免疫治疗研究现状

doi: 10.12376/j.issn.2097-0501.2022.01.006

北京大学肿瘤医院暨北京市肿瘤防治研究所，恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142

详细信息

通信作者:
沈琳，E-mail: shenlin@bjmu.edu.cn

中图分类号: R735;R979.1
计量
- 文章访问数: 2422
- HTML全文浏览量: 74
- PDF下载量: 36
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-13
- 修回日期: 2022-01-05

The Advance in Research into Immunotherapy for Neuroendocrine Carcinoma of Digestive System

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

More Information

Corresponding author: SHEN Lin, E-mail: shenlin@bjmu.edu.cn

摘要

摘要: 神经内分泌肿瘤是少见的异质性肿瘤，不同病理类型、分化程度、分级和分期，治疗和转归存在很大差异。其中晚期神经内分泌癌恶性度高、预后差、可选药物较少、缺乏有效治疗手段。免疫治疗是近几年肿瘤治疗领域的最重要的突破，在多种实体瘤中显示出较好疗效。以程序性死亡受体1及其配体(programmed cell death 1/programmed cell death-ligand 1, PD-1/PD-L1)单抗为代表的免疫治疗在神经内分泌癌治疗中的作用，国内外也进行了大量探索性研究，这些研究结果对目前免疫治疗在神经内分泌癌临床应用提供了指导，也为未来相关研究开展提供了重要参考。本文对该领域的主要研究数据进行了总结和分析。
- 神经内分泌癌 /
- 免疫治疗 /
- 抗血管生成药物 /
- 生物标记物
Abstract: Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is a rare heterogeneous tumor. The heterogeneity in pathology, differentiation, grade and clinical stages results in different prognosis and treatment strategy. Patients with recurrent or metastatic NEN have limited treatment options and poor prognosis.Programmed cell death 1(PD-1) blockade has played indispensable roles in management of cancers recently.Immunotherapy is being explored in NENs in the world with emerging clinical trials. The results of the trials provide evidence and guidance in the application of NEC.The article analizes and summarizes of the findings of major investigations in this field.
- neuroendocrine carcinoma /
- immunotherapy /
- anti-angiogenic drugs /
- biomarker
注释:

作者贡献：陆明负责撰写和校对；张盼盼负责文献检索和翻译；沈琳负责撰写、校对和修订论文。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(10)

[1]	Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma[J]. N Engl J Med, 2016, 374: 2542-2552. doi: 10.1056/NEJMoa1603702
[2]	Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial[J]. J Immunother Cancer, 2018, 6: 7. doi: 10.1186/s40425-017-0310-x
[3]	Yao J, Strosberg J, Fazio N, et al. 1308O Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)[J]. Ann Oncol, 2018, 29(suppl 8): mdy293. 001.
[4]	Lu M, Zhang P, Zhang Y, et al. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial[J]. Clin Cancer Res, 2020, 26: 2337-2345. http://www.researchgate.net/publication/339418349_Efficacy_Safety_and_Biomarkers_of_Toripalimab_in_Patients_with_Recurrent_or_Metastatic_Neuroendocrine_Neoplasms_A_Multiple-Center_Phase_Ib_Trial
[5]	Rodriguez-Freixinos V, Chan D, Doherty M, et al. Avelu-mab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)[C]. ENETS 2020, Abstract 109.
[6]	Patel SP, Othus M, Chae YK, et al. A Phase Ⅱ Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors[J]. Clin Cancer Res, 2020, 26: 2290-2296. doi: 10.1158/1078-0432.CCR-19-3356
[7]	Girard N, Mazieres J, Otto J, et al. Nivolumab (nivo) +/- ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)[J]. Ann Oncol, 2021, 32: S1318-S1318. doi: 10.1016/j.annonc.2021.08.2119
[8]	Capdevila J, Teule A, López C, et al. A multi-cohort phase Ⅱ study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)[J]. 2020 ESMO, Abstract 1157O.
[9]	Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39: 619-630. doi: 10.1200/JCO.20.01055
[10]	Lu M, Cao Y, Gong J, et al. A Phase Ⅰ Trial of Surufa-tinib plus Toripalimab in Patients with Advanced Solid Tumor[C]. 2020 AACR Annual Meeting, Abstract 9563.